Fenfluramine treatment in infantile autism neurochemical, electrophysiological, and behavioral effects

Gerald J. August, Naftali Raz, Andrew Papanicolaou, Teresa Davis Baird, Sharon L. Hirsh, Louise L. Hsu

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

As part of a multicenter, collaborative project, response to fenfluramine was assessed in 10 autistic outpatients. After 4 months of treatment, blood serotonin concentrations decreased an average of 60 per cent and returned to pretreatment levels after 2 months on placebo. This reduction was accompanied by a decrease in certain behavioral symptoms, including motor activity, distractibility, and mood disturbances. Baseline evoked potential recordings indicated that autistic patients tended to have a larger amplitude of the P3 component to frequent tones as compared to age-matched controls. A tendency toward “normalization” of the P3 effect was observed during the medication trial and during the final placebo period. Treatment response was not related to initial serotonin levels, and no major clinical side effects were associated with fenfluramine.

Original languageEnglish (US)
Pages (from-to)604-612
Number of pages9
JournalJournal of Nervous and Mental Disease
Volume172
Issue number10
DOIs
StatePublished - Jan 1 1984

Fingerprint

Fenfluramine
Autistic Disorder
Serotonin
Placebos
Behavioral Symptoms
Evoked Potentials
Motor Activity
Outpatients
Therapeutics

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

Fenfluramine treatment in infantile autism neurochemical, electrophysiological, and behavioral effects. / August, Gerald J.; Raz, Naftali; Papanicolaou, Andrew; Baird, Teresa Davis; Hirsh, Sharon L.; Hsu, Louise L.

In: Journal of Nervous and Mental Disease, Vol. 172, No. 10, 01.01.1984, p. 604-612.

Research output: Contribution to journalArticle

August, Gerald J. ; Raz, Naftali ; Papanicolaou, Andrew ; Baird, Teresa Davis ; Hirsh, Sharon L. ; Hsu, Louise L. / Fenfluramine treatment in infantile autism neurochemical, electrophysiological, and behavioral effects. In: Journal of Nervous and Mental Disease. 1984 ; Vol. 172, No. 10. pp. 604-612.
@article{02fa850c2c2b41d793ce13b90a51eb37,
title = "Fenfluramine treatment in infantile autism neurochemical, electrophysiological, and behavioral effects",
abstract = "As part of a multicenter, collaborative project, response to fenfluramine was assessed in 10 autistic outpatients. After 4 months of treatment, blood serotonin concentrations decreased an average of 60 per cent and returned to pretreatment levels after 2 months on placebo. This reduction was accompanied by a decrease in certain behavioral symptoms, including motor activity, distractibility, and mood disturbances. Baseline evoked potential recordings indicated that autistic patients tended to have a larger amplitude of the P3 component to frequent tones as compared to age-matched controls. A tendency toward “normalization” of the P3 effect was observed during the medication trial and during the final placebo period. Treatment response was not related to initial serotonin levels, and no major clinical side effects were associated with fenfluramine.",
author = "August, {Gerald J.} and Naftali Raz and Andrew Papanicolaou and Baird, {Teresa Davis} and Hirsh, {Sharon L.} and Hsu, {Louise L.}",
year = "1984",
month = "1",
day = "1",
doi = "10.1097/00005053-198410000-00003",
language = "English (US)",
volume = "172",
pages = "604--612",
journal = "Journal of Nervous and Mental Disease",
issn = "0022-3018",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Fenfluramine treatment in infantile autism neurochemical, electrophysiological, and behavioral effects

AU - August, Gerald J.

AU - Raz, Naftali

AU - Papanicolaou, Andrew

AU - Baird, Teresa Davis

AU - Hirsh, Sharon L.

AU - Hsu, Louise L.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - As part of a multicenter, collaborative project, response to fenfluramine was assessed in 10 autistic outpatients. After 4 months of treatment, blood serotonin concentrations decreased an average of 60 per cent and returned to pretreatment levels after 2 months on placebo. This reduction was accompanied by a decrease in certain behavioral symptoms, including motor activity, distractibility, and mood disturbances. Baseline evoked potential recordings indicated that autistic patients tended to have a larger amplitude of the P3 component to frequent tones as compared to age-matched controls. A tendency toward “normalization” of the P3 effect was observed during the medication trial and during the final placebo period. Treatment response was not related to initial serotonin levels, and no major clinical side effects were associated with fenfluramine.

AB - As part of a multicenter, collaborative project, response to fenfluramine was assessed in 10 autistic outpatients. After 4 months of treatment, blood serotonin concentrations decreased an average of 60 per cent and returned to pretreatment levels after 2 months on placebo. This reduction was accompanied by a decrease in certain behavioral symptoms, including motor activity, distractibility, and mood disturbances. Baseline evoked potential recordings indicated that autistic patients tended to have a larger amplitude of the P3 component to frequent tones as compared to age-matched controls. A tendency toward “normalization” of the P3 effect was observed during the medication trial and during the final placebo period. Treatment response was not related to initial serotonin levels, and no major clinical side effects were associated with fenfluramine.

UR - http://www.scopus.com/inward/record.url?scp=0021748950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021748950&partnerID=8YFLogxK

U2 - 10.1097/00005053-198410000-00003

DO - 10.1097/00005053-198410000-00003

M3 - Article

VL - 172

SP - 604

EP - 612

JO - Journal of Nervous and Mental Disease

JF - Journal of Nervous and Mental Disease

SN - 0022-3018

IS - 10

ER -